What Arbor Pharmaceuticals does

Arbor Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006 and headquartered in the United States (Atlanta, GA), focused on developing and commercializing difficult-to-formulate medicines for overlooked patient populations — particularly pediatric, geriatric, and institutional patients. The company's core capability is specialized formulation technology, enabling liquid, customized-dose, and otherwise hard-to-manufacture drug products across therapeutic categories including central nervous system, cardiovascular, anti-infective, oncology, endocrinology, and gastrointestinal. The product portfolio spans 50+ medicines across 10 dosage forms and 10 therapeutic areas, with a global footprint reaching over 50 countries.

The business operates a traditional specialty pharma go-to-market: an enterprise field-sales force calling on institutional healthcare facilities (hospitals, nursing homes, assisted living facilities) supplemented by retail pharmacy distribution channels in the U.S. Revenue is generated through prescription pharmaceutical sales under negotiated contracts with institutional buyers and healthcare providers, with pricing not publicly disclosed. Recent strategic activity indicates active portfolio expansion, including the 2026 acquisition of CONTRAVE for obesity/weight management, FDA approval of Aprepitant Injectable Emulsion in oncology supportive care, and prior acquisitions such as XenoPort (2016) in CNS.

The company is backed by institutional healthcare-focused investors including KKR (2014) and Signet Healthcare Partners (2010), and is led by Chairman Jason Wild and President & CEO Ed Schutter. The company describes a "Next-Gen Commercial Model" leveraging data, analytics, and AI-driven digital tools for stakeholder engagement, though evidence of deep proprietary AI capability is limited.

Name

Arbor Pharmaceuticals

Website

https://arborpharma.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Arbor Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006 that develops and commercializes difficult-to-formulate medicines for pediatric, geriatric, and institutional patient populations across 50+ countries and 10 therapeutic areas.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Specialty pharmaceuticals
• Pediatric drug formulations
• Institutional pharmaceutical sales
• Prescription drug manufacturing
• Geriatric medicine formulations

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceutical Sales: Sale of prescription medications to institutional and retail customers in the U.S. market, including hospitals, nursing homes, assisted living facilities, and retail pharmacy channels.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Arbor Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and sells prescription drug products for pediatric, geriatric, and institutional patient populations. Its portfolio focuses on difficult-to-formulate medicines — including liquid and customized-dose forms — across central nervous system, cardiovascular, anti-infective, and oncologic therapeutic areas, sold to hospitals, nursing homes, assisted living facilities, and retail pharmacy channels in the U.S.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty Prescription Pharmaceutical Portfolio A portfolio of prescription drug products in difficult-to-formulate formats (including liquid and customized-dose forms) sold to hospitals, nursing homes, assisted living facilities, and retail pharmacy channels for use in pediatric, geriatric, and institutional patient populations with specialized medication needs.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• ANI Pharmaceuticals: ANI is a U.S. specialty pharmaceuticals company that acquires, develops, and markets branded and generic prescription drugs across multiple therapeutic areas, with a comparable focus on niche patient populations and institutional channels.
• Amneal Pharmaceuticals: Amneal combines specialty, branded, and complex generics with a broad therapeutic portfolio and manufacturing capabilities, mirroring Arbor's mid-sized U.S. specialty pharma profile and product-acquisition strategy.
• Mallinckrodt Pharmaceuticals: Mallinckrodt is a specialty pharmaceutical company focused on difficult-to-manufacture branded and specialty generic products across CNS, autoimmune, and hospital channels — closely aligned with Arbor's specialty/institutional focus.
• Upsher-Smith Laboratories: Upsher-Smith is a U.S. specialty pharma marketing branded and generic prescription products across CNS, dermatology, and women's health — a similar mid-sized, vertically focused portfolio to Arbor's.
• Padagis: Padagis is a specialty pharmaceuticals company focused on complex generics, dermatology, and OTC products, providing a direct comparison for Arbor's difficult-to-formulate, niche-prescription business model.
• Endo Pharmaceuticals: Endo is a specialty pharma with a diversified portfolio spanning sterile injectables, generics, and branded specialty products, often used as a comparable for Arbor's mid-cap specialty franchise economics.
• Azurity Pharmaceuticals: Azurity is a privately held specialty pharma delivering innovative medicines for overlooked patients across 50+ countries and 10 therapeutic areas — closely matching Arbor's product portfolio, mission, and institutional GTM described in the source data.
• Jazz Pharmaceuticals: Jazz is a specialty pharma company focused on CNS and oncology products, with comparable institutional sales infrastructure and a similar strategy of acquiring and developing differentiated specialty therapeutics.

Broad incumbents

• Perrigo Company: Perrigo is a large specialty and consumer-focused pharma with significant U.S. prescription and OTC exposure, providing a broader-market comparable for Arbor's institutional and retail channels.
• Bausch Health Companies: Bausch Health operates a much larger specialty pharma and consumer health portfolio, but its branded specialty division competes in overlapping therapeutic categories with Arbor and is a comparable for specialty pharma scale dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/129233577093828
• LinkedInlinkedin.com/company/arbor-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arbor Pharmaceuticals